You are here: Home: Meet The Professors Vol. 1 2003: Case 2: Select publications

 

Select publications: Tumor markers in metastatic breast cancer

Bast RC Jr et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19(6):1865-78. Abstract.

Clinton SR et al. A comparative study of four serological tumor markers for the detection of breast cancer. Biomed Sci Instrum 2003;39:408-14. Abstract.

Duffy MJ. Biochemical markers in breast cancer: Which ones are clinically useful? Clin Biochem 2001;34(5):347-52. Abstract.

Gion M et al. CA27.29: A valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 2001;37(3):355-63. Abstract.

Gion M et al. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: A prospective study on 859 patients. Cancer J 2001;7(3):181-90. Abstract.

Guadagni F et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: A prospective longitudinal study. Clin Cancer Res 2001;7(8):2357-62. Abstract.

Jager W et al. Serial CEA and CA 15-3 measurements during follow-up of breast cancer patients. Anticancer Res 2000;20(6D):5179-82. Abstract.

Kurebayashi J et al. Significance of Serum Carcinoembryonic Antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: A large-scale retrospective study. Breast Cancer 2003;10(1):38-44. Abstract.

Lauro S et al. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res 1999;19(4C):3511-5. Abstract.

Lufter D et al. A comparison of bone-related biomarkers and CA27.29 to assess response to treatment of osseous metastatic breast cancer. Anticancer Res 2000;20(6D):5099-105. Abstract.

Robertson JF et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Eur J Cancer 1999;35(1):47-53. Abstract.

Smith TJ et al. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999;17(3):1080-2. Abstract.

Sutterlin M et al. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer. Anticancer Res 1999;19(4A):2567-70. Abstract.

Valenzuela P et al. The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer. Eur J Gynaecol Oncol 2003;24(1):60-2. Abstract.

Table of Contents Top of Page 

 

Home · Search

 
CME Information
Faculty
Editor's Note
 
CASE 1: Disease recurrence and brachial plexopathy during the third trimester of pregnancy
- Select publications
 
CASE 2: Unresectable local recurrence in the pectoralis major after breast-conserving
surgery
- Select publications
 
CASE 3: Pulmonary metastases and mild shortness of breath
- Select publications
 
CASE 4: HER2-positive metastases to the lung and residual local breast cancer after lumpectomy
- Select publications
 
CASE 5: Liver metastases and mild hepatic encephalopathy
- Select publications
 
CASE 6: Ascites and pleural effusion ten years after primary breast cancer
- Select publications
Home · Contact us
Terms of use and general disclaimer